MENLO PARK, Calif.--(BUSINESS WIRE)-- Octave® Bioscience, Inc., a leading precision care company that delivers a new standard for managing multiple sclerosis (MS) and other neurodegenerative diseases, ...
OCTAVE-DUO Study To Evaluate Novavax' Vaccine Candidate In Participants With Impaired Immune Systems
(RTTNews) - Novavax, Inc. (NVAX) said its recombinant nanoparticle protein vaccine candidate is being studied in OCTAVE-DUO in the UK to evaluate the safety and immunogenicity of a third COVID-19 ...
OXFORD, England, Jun 17, 2014 (BUSINESS WIRE) -- PsiOxus Therapeutics Ltd. (PsiOxus), an award-winning biotechnology company developing innovative new treatments for cancer, today announced the first ...
A new clinical trial to determine whether a third dose of vaccine will improve the immune response for people who have weakened immune systems is launching in the UK. The study, OCTAVE DUO, will offer ...
NEW YORK, NY, May 09, 2023 (GLOBE NEWSWIRE) -- Violet, the first health equity platform, released a new case study today with national behavioral health practice Octave, showing the results of care ...
A major clinical trial has found that an additional COVID 19 vaccine dose led to the majority of clinically extremely vulnerable people mounting defensive antibodies against Covid-19. New research ...
Up to 5000 immunocompromised people from across the UK are set to be vaccinated as part of the Octave study to investigate COVID-19 vaccine efficacy in those with impaired immune systems. Thus far ...
UK Government Awards £1.7M Grant to PsiOxus Therapeutics for Second Phase I/II Clinical Trial of Cancer Vaccine 'OCTAVE' Study Will Assess ColoAd1 in Patients with Ovarian Cancer OXFORD, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results